On this episode of Not So Different, we recap some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.
On this episode, we’re going to be recapping some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.
Show notes
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders
Tocilizumab Biosimilar LZM008 Demonstrates PK Equivalence in Healthy Participants
RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.